Antiplatelet antibodies detected by the MAIPA assay in newly diagnosed immune thrombocytopenia are associated with chronic outcome and higher risk of bleeding
- 633 Downloads
Immune thrombocytopenia (ITP) results in part from the presence of platelet antibodies, which can be demonstrated by the Monoclonal Antibody-Specific Immobilization of Platelet Antigens (MAIPA) assay. The aim of our study was to correlate the presence of antiplatelet autoantibodies and the natural history of ITP. We performed a retrospective, single-center study of 108 adults with newly diagnosed ITP who had indirect MAIPA assay performed at disease onset. Chronic ITP was defined by the presence of thrombocytopenia after 1 year. Bleeding diathesis was evaluated with a bleeding score. At baseline, patients with a positive indirect MAIPA have a greater bleeding score than patients with negative MAIPA assay [median (interquartile) = 8 (6–12) vs 2 (0–6), p = 0.002]. Patients with a positive indirect MAIPA also had a higher rate of chronic ITP (92.9 vs 68.7 %, p = 0.06). In multivariate analysis, a positive indirect MAIPA result and a platelet count at onset ≥10 × 109/L remained independently associated with chronic ITP [adjusted OR (aOR) = 8.01; 95 % confidence interval (CI), 0.98–66.6; p = 0.05 and aOR = 3.09; 95 % CI, 1.18–8.10; p = 0.02, respectively]. Furthermore, when we analyzed together the results of direct (n = 41) and indirect MAIPA, the same results were observed. Thus, indirect MAIPA positivity at disease onset is associated with more severe hemorrhage and predicts a chronic course in adult ITP patients. MAIPA assay could be useful in the management of ITP patients when it is performed at diagnosis.
KeywordsImmune thrombocytopenia MAIPA assay Chronic ITP Platelet autoantibodies
The authors would like to gratefully thank Aurélie Le Thuaut for her technical help in statistical analysis. DG, BG and PB designed the study. BG, PB, MK, MM enrolled the patients. DG and LL recorded the data of the study. FCP and FRT performed the statistical analysis. KL, LC and PB performed MAIPA test. DG, FCP, MK, MM, BG and PB wrote the manuscript.
- 1.Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393PubMedCrossRefGoogle Scholar
- 5.Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115:168–186PubMedCrossRefGoogle Scholar
- 10.(2003) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120: 574–596Google Scholar
- 11.Arnold DM, Santoso S, Greinacher A, (2012) Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia. J Thromb HaemostGoogle Scholar
- 12.George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3–40PubMedGoogle Scholar
- 14.Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DEG PG, Koike T, Meroni PL, Reber G, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306PubMedCrossRefGoogle Scholar
- 16.Purpura thrombopénique immunologique de l'enfant et de l'adulte. Protocole national de diagnostic et de soins. Haute Autorité de Santé. http://www.hassante.fr/portail/upload/docs/application/pdf/2009-12/ald_2_pnds_pti_imune_enft_adulte_web.pdf
- 23.Berchtold P, Muller D, Beardsley D, Fujisawa K, Kaplan C, Kekomaki R, Lipp E, Morell-Kopp MC, Kiefel V, McMillan R, von dem Borne AE, Imbach P (1997) International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 96:477–483PubMedCrossRefGoogle Scholar
- 26.Fabris F, Scandellari R, Ruzzon E, Randi ML, Luzzatto G, Girolami A (2004) Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 103:4562–4564PubMedCrossRefGoogle Scholar